SCHEMBL7125937

SCHEMBL7125937

CC(=O)Oc1c(C)c(C)c2c(c1C)C(=O)CC(C)(COc1ccc(N)cc1)O2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PDE4A P27815 1/20 0.36
PDE3A Q14432 1/20 0.36
MAPT P10636 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
TTPA P49638 2/20 0.32
PPARG P37231 1/20 0.32
ALOX5 P09917 1/20 0.31
KDM4E B2RXH2 4/20 0.31
ALDH1A1 P00352 4/20 0.31
GAA P10253 4/20 0.31
HPGD P15428 3/20 0.31
CASP1 P29466 3/20 0.31
HSD17B10 Q99714 3/20 0.31
GLA P06280 2/20 0.31
CASP7 P55210 1/20 0.31
NR3C2 P08235 1/20 0.31
PREP P48147 1/20 0.30
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9632620 0.89 MEN1 (0.33) MEN1KMT2APDE4APDE3ATTPA
SCHEMBL8177483 0.87 KMT2A (0.39) MEN1KMT2APDE4APDE3AMAPT
SCHEMBL8980246 0.84 MEN1 (0.44) MEN1KMT2AMAPTTDP1PPARG
SCHEMBL9632167 0.84 MEN1 (0.34) MEN1KMT2APDE4APDE3A
SCHEMBL10641941 0.84 PPARG (0.39) MEN1KMT2APDE4APDE3AMAPT
SCHEMBL9632908 0.83 DDB1 (0.34) MEN1KMT2AMAPTTDP1KDM4E
SCHEMBL10635866 0.82 PPARG (0.35) MEN1KMT2APDE4APDE3AMAPT
SCHEMBL7487350 0.82 MEN1 (0.52) MEN1KMT2APDE4APDE3AMAPT
SCHEMBL10640678 0.81 CYP3A4 (0.49) MEN1KMT2AMAPTTDP1PPARG
SCHEMBL9632649 0.81 PPARG (0.31) MEN1KMT2AMAPTTDP1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030134859-A1 PPAR-gamma modulator SANKYO COMPANY, LIMITED (JP) 2003-07-17 US disclosed
EP-1277729-A1 PPAR (GAMMA) MODULATORS Sankyo Company, Limited (JP) 2003-01-22 EP disclosed
WO-2000008009-A1 PROCESS FOR THE PREPARATION OF 2-(AMINOPHENOXYMETHYL) CHROMANS SANKYO COMPANY, LIMITED (JP) 2000-02-17 WO disclosed
EP-0139421-B1 THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SANKYO COMPANY LIMITED (JP) 1988-04-27 EP disclosed
US-4572912-A Thiazolidine derivatives, their preparation and compositions containing them SANKYO COMPANY LIMITED (JP) 1986-02-25 US disclosed
EP-0139421-A1 Thiazolidine derivatives, their preparation and compositions containing them SANKYO COMPANY LIMITED (JP) 1985-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134859-A1 PPAR-gamma modulator PPARG, PPARA, PPARD MEN1 4865/4885KMT2A 3291/4885PDE4A 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.